润本股份 20250618 摘要 润本公司通过多品类战略，从驱蚊、婴童护理拓展至青少年护肤市场， 并成功推出如蛋黄油面霜和婴童防晒啫喱等差异化产品，验证了其推新 能力和市场适应性。2024 年 Q4 抖音蛋黄油面霜 GMV 达 4,500 万以上， 同比增速接近 660 倍。 2025 年，润本公司重点布局驱蚊、防晒和青少年护肤三大板块。驱蚊 产品仍是支柱，防晒新品销售良好，青少年护肤产品潜力巨大。公司凭 借自有工厂、多渠道布局和新品研发能力，具备中长期投资价值。 母婴护理市场竞争分散，但润本作为头部企业，受益于品牌背书和高复 购率（如面霜类产品复购率达 50%），具有强者恒强的属性。该市场仍 有较大增长空间，等待公司进一步抢占市场份额。 公司将业务拓展至青少年护肤市场，覆盖 0-18 岁年龄段，减少了营销 挑战。青少年护肤市场潜力巨大，2023 年全网成交额约 36 亿元，公司 可通过差异化竞争和渠道运营，打造大单品。 润本在驱蚊液领域持续创新，推出定时加热、远程操控等智能产品，并 通过抖音渠道成功推广带定时功能加热器，推动业绩增长。公司选择有 潜力的细分市场，进行品类创新和拓展。 Q&A 润本公司在 20 ...

Investment Rating - The investment rating for Runben Co., Ltd. (603193) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on recent performance and product launches [1]. Core Views - The report highlights the successful promotion of new sunscreen products and the promising potential of the youth series, indicating a strong growth trajectory for the company [1][2]. - The company achieved a revenue of 1.318 billion yuan in 2024, reflecting a year-on-year growth of 27.6%, and a net profit of 300 million yuan, up 32.8% [1][4]. - The first quarter of 2025 saw a revenue of 240 million yuan, marking a 44.0% increase year-on-year, with a net profit of 44 million yuan, up 24.6% [1]. Summary by Relevant Sections Financial Performance - In 2024, the company's baby and child care products generated revenue of 690 million yuan, a 32.4% increase year-on-year, with a gross margin of 59.8% [2]. - The first quarter of 2025 for baby and child care products showed a revenue of 179 million yuan, a significant 65.6% increase year-on-year, driven by higher average prices of new products [2]. - The company's gross margin and net profit margin for Q1 2025 were 57.7% and 18.4%, respectively, with operational cash flow showing improvement [3]. Product Development - The sunscreen gel launched in February 2025 is expected to see rapid sales growth due to its favorable skin feel and cost-effectiveness [2]. - The mosquito repellent segment also showed growth, with revenue of 439 million yuan in 2024, a 35.4% increase year-on-year, and continued expansion in outdoor mosquito repellent products [2]. Profit Forecast - The forecast for net profit from 2025 to 2027 is projected at 400 million yuan, 530 million yuan, and 704 million yuan, respectively, with corresponding P/E ratios of 36X, 27X, and 20X [3].

Investment Rating - The investment rating for Runben Co., Ltd. (603193) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on recent performance and product launches [1]. Core Views - The report highlights the successful promotion of new sunscreen products and the promising potential of the youth series, indicating a strong growth trajectory for the company [1][2]. - The company achieved a revenue of 1.318 billion yuan in 2024, reflecting a year-on-year growth of 27.6%, and a net profit of 300 million yuan, up 32.8% year-on-year [1][4]. - The first quarter of 2025 saw a revenue of 240 million yuan, representing a 44% increase year-on-year, with a net profit of 44 million yuan, up 24.6% year-on-year [1]. Summary by Relevant Sections Financial Performance - In 2024, the company's baby care products generated revenue of 690 million yuan, a 32.4% increase year-on-year, with a gross margin of 59.8% [2]. - The first quarter of 2025 for baby care products showed a revenue of 179 million yuan, a remarkable 65.6% increase year-on-year, driven by higher average prices of new products [2]. - The company's gross margin for Q1 2025 was 57.7%, with a net profit margin of 18.4% [3]. Product Development - The sunscreen gel launched in February 2025 is expected to see rapid sales growth due to its favorable skin feel and cost-effectiveness [2]. - The mosquito repellent segment also showed strong performance, with revenue of 439 million yuan in 2024, a 35.4% increase year-on-year [2]. Profit Forecast - The forecast for net profit for Runben Co., Ltd. from 2025 to 2027 is projected to be 400 million yuan, 530 million yuan, and 704 million yuan respectively, with corresponding P/E ratios of 36X, 27X, and 20X [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [5][12]. Core Insights - The company achieved steady revenue and profit growth in 2024, with a revenue of 1.318 billion yuan, a year-on-year increase of 27.61%, and a net profit of 300 million yuan, up 32.8% year-on-year. The first quarter of 2025 saw accelerated growth, with revenue reaching 240 million yuan, a 44% increase year-on-year, and a net profit of 44 million yuan, up 24.6% year-on-year [2][5]. Revenue and Profitability - In 2024, the company's gross margin was 58.17%, an increase of 1.82 percentage points year-on-year, while the net margin was 22.77%, up 0.89 percentage points year-on-year. The sales expense ratio increased to 28.80%, while the management expense ratio decreased to 2.45% [2][5]. Product Performance - The baby care series generated 690 million yuan in revenue, a 32.42% increase year-on-year, while the mosquito repellent series saw revenue of 439 million yuan, up 35.39% year-on-year. The essential oil series achieved 158 million yuan in revenue, a 7.88% increase year-on-year [3]. Channel Strategy - Online sales accounted for a significant portion of revenue, with direct sales, platform distribution, and platform agency sales generating 774 million yuan, 165 million yuan, and 31 million yuan respectively, all showing year-on-year growth. The company is actively building a comprehensive sales network, maintaining a leading market share on platforms like Tmall, JD, and Douyin [4]. Future Earnings Forecast - The company is expected to achieve net profits of 394 million yuan, 507 million yuan, and 635 million yuan for the years 2025, 2026, and 2027 respectively, with corresponding earnings per share (EPS) of 0.97 yuan, 1.25 yuan, and 1.57 yuan [5][7].

股票简称：润本股份 股票代码：603193 润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 二〇二三年十月十六日 特别提示 润本生物技术股份有限公司（以下简称"润本股份"、"发行人"、"本 公司"或"公司"）股票将于 2023 年 10 月 17 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素， 在新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明与提示 本上市公告书部分表格中单项数据加总数与表格合计数可能存在微小差 异，均因计算过程中的四舍五入所形成。 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市 初期的投资风险，广大投资者应充分了解交易风险、理性参与新股交易。 具体而言，上市初期的风险包括但不限于以下几种： （一）涨跌幅限制放宽带来的股票交易风险 本公司及全体 ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 润本生物技术股份有限公司 招股说明书 | 发行股票类型： | 人民币普通股（A 股） | | | | | --- | --- | --- | --- | --- | | 发行股数： | 本次发行 6,069.00 | | ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 （广州经济技术开发区新庄五路 3 号） 以正式公告的招股说明书作为投资决定的依据。 大成国际大厦 20 楼 2004 室 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 | > | | - ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 | 发行股票类型： | 人民币普通股（A 股） | | --- | --- | | 发行股数： | 本次发行不超过 6,069.00 万股，占公司发行后总股本的 | | | 比例不低于 15%，本次发行股份均为公开发行的新股， | | | 公司原有股东不公开发售股份。 | | 每股面值： | 元人民币 1.00 | | 每股发行价格： | 【】元人民币 | | 预计发行日期： | 【】年【】月【】日 | | 拟上市的证券交易所和板块： | 上海证券交易所主板 | | 发行后总股本： | 不超过 40,459.3314 万股 | | 保荐人（主承销 ...